Quest Diagnostics DGX
Quest Diagnostics is an American company that provides diagnostic services, clinical laboratory testing, and health information solutions, operating an extensive network of laboratories and specimen collection centers. Quest Diagnostics shows solid growth (revenue +10.2%, earnings +15%) with an operating margin of 15.25%, but the valuation (P/E 25.09) already prices in much of the good news, and the threat of Medicare reimbursement cuts is a risk to watch.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Quest Diagnostics is an American company that provides diagnostic services, clinical laboratory testing, and health information solutions, operating an extensive network of laboratories and specimen collection centers. Quest Diagnostics shows solid growth (revenue +10.2%, earnings +15%) with an operating margin of 15.25%, but the valuation (P/E 25.09) already prices in much of the good news, and the threat of Medicare reimbursement cuts is a risk to watch.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.2 |
| Quality / Moat | 5.5 |
| Valuation | 4.8 |
| Growth | 6.9 |
| Dividend | 5.6 |
| Momentum | 7.4 |
| Risk & Context | 7.8 |
OVERALL SCORE: 6.1/10
Context and risks
Quest Diagnostics has significant exposure to Medicare, and reimbursement cuts are a recurring regulatory risk that can compress margins. Pricing pressure on laboratory services is an active sector risk.
News considered in the analysis
- Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? — Artículo de Zacks que resume la revalorización ya ocurrida; no aporta información nueva sobre fundamentales.
- Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch — La integración con Apple Health podría ampliar el acceso a los servicios de laboratorio de Quest, un potencial catalizador de crecimiento aún no totalmente descontado.
- Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns — Los recortes en los reembolsos de Medicare son una amenaza material para los ingresos de Quest, dado su alta exposición a este pagador; el mercado ya ha ajustado parte del precio, pero persiste la incertidumbre.
- Stock Market Today: Dow Skids But Apple Eyes A Buy Point; Filing Says Trump Makes These Trades — Titular genérico de mercado sin información específica sobre Quest Diagnostics.
- Why Quest Diagnostics Holdings Stock Dropped Today — La caída ya se ha producido y está reflejada en el precio; el motivo concreto no se detalla, pero es información ya descontada.
Verdict: Hold; the company has solid fundamentals, but regulatory uncertainty and a not particularly cheap valuation limit the upside potential in the short term.
Main risk: Exposure to Medicare and the possibility of further cuts in laboratory test reimbursements, which could compress margins and revenue growth.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →